Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors

Journal of Immunology

Volumn 176, Issue 12, 2006, Pages 7308-7316

  Purbhoo, Marco A ^a   Sutton, Deborah H ^a   Brewer, Joanna E ^a   Mullings, Rebecca E ^a   Hill, Maxine E ^a   Mahon, Tara M ^a   Karbach, Julia ^b   Jäger, Elke ^b   Cameron, Brian J ^a   Lissin, Nikolai ^a   Vyas, Paresh ^c   Chen, Ji Li ^c   Cerundolo, Vincenzo ^c   Jakobsen, Bent K ^a  

^a Avidex Ltd   (United Kingdom)

^b KRANKENHAUS NORDWEST   (Germany)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; EPITOPE; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; NY ESO 1 ANTIGEN; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMAGING; IMMUNOCYTOCHEMISTRY; MYELOMA CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR AFFINITY;

EID: 33744938168     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.12.7308     Document Type: Article

References (45)

1. Chen, Y. T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody. screening. Proc. Natl. Acad. Sci. USA 94: 1914-1918.
2. van Rhee, F., S. M. Szmania, F. Zhan, S. K. Gupta, M. Pomtree, P. Lin, R. B. Batchu, A. Moreno, G. Spagnoli, J. Shaughnessy, and G. Tricot. 2005. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 105: 3939-3944.
3. Jager, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, L. J. Old, and A. Knuth. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265-270.
4. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 60: 4499-4506.
5. + cancers. Proc. Natl. Acad. Sci. USA 97: 12198-12203.
6. + T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J. Clin. Invest. 110: 1813-1822.
7. + T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc. Natl. Acad. Sci. USA 99: 11813-11818.
8. Palmowski, M. J., L. Lopes, Y. Ikeda, M. Salio, V. Cerundolo, and M. K. Collins. 2004. Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol. 172: 1582-1587.
9. Jardetzky, T. S., W. S. Lane, R. A. Robinson, D. R. Madden, and D. C. Wiley. 1991. Identification of self peptides bound to purified HLA-B27. Nature 353: 326-329.
10. van Els, C. A., C. A. Herberts, E. van der Heeft, M. C. Poelen, J. A. van Gaans-van den Brink, A. van der Kooi, P. Hoogerhout, G. Jan ten Hove, H. D. Meiring, and A. P. de Jong. 2000. A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains. Eur. J. Immunol. 30: 1172-1181.
11. Herberts, C. A., K. J. Stittelaar, E. van der Heeft, J. van Gaans-Van den Brink, M. C. Poelen, P. J. Roholl, L. J. van Alphen, C. J. Melief, A. P. de Jong, and C. A. van Els. 82:2131. 2001. A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway. J. Gen. Virol.
12. Wang, W., P. H. Gulden, R. A. Pierce, J. Shabanowitz, S. T. Man, D. F. Hunt, and V. H. Engelhard. 1997. A naturally processed peptide presented by HLA-A*0201 is expressed at low abundance and recognized by an alloreactive CD8+ cytotoxic T cell with apparent high affinity. J. Immunol. 158: 5797-5804.
13. Pascolo, S., M. Schirle, B. Guckel, T. Dumrese, S. Stumm, S. Kayser, A. Moris, D. Wallwiener, H. G. Rammensee, and S. Stevanovic. 2001. A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. Cancer Res. 61: 4072-4077.
14. Schirle, M., W. Keilholz, B. Weber, C. Gouttefangeas, T. Dumrese, H. D. Becker, S. Stevanovic, and H. G. Rammensee. 2000. Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30: 2216-2225.
15. Chames, P., S. E. Hufton, P. G. Coulie, B. Uchanska-Ziegler, and H. R. Hoogenboom. 2000. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proc. Natl. Acad. Sci. USA 97: 7969-7974.
16. Denkberg, G., C. J. Cohen, A. Lev, P. Chames, H. R. Hoogenboom, and Y. Reiter. 2002. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc. Natl. Acad. Sci. USA 99: 9421-9426.
17. Held, G., M. Matsuo, M. Epel, S. Gnjatic, G. Ritter, S. Y. Lee, T. Y. Tai, C. J. Cohen, L. J. Old, M. Pfreundschuh, Y. Reiter, H. R. Hoogenboom, and C. Renner. 2004. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Eur. J. Immunol. 34: 2919-2929.
18. Cohen, C. J., N. Hoffmann, M. Farago, H. R. Hoogenboom, L. Eisenbach, and Y. Reiter. 2002. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res. 62: 5835-5844.
19. Cohen, C. J., G. Denkberg, A. Lev, M. Epel, and Y. Reiter. 2003. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J. Mol. Recognit. 16: 324-332.
20. 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. J. Immunol. 174: 1462-1471.
21. Card, K. F., S. A. Price-Schiavi, B. Liu, E. Thomson, E. Nieves, H. Belmont, J. Builes, J. A. Jiao, J. Hernandez, J. Weidanz, et al. 2004. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol. Immunother. 53: 345-357.
22. Epel, M., J. D. Ellenhom, D. J. Diamond, and Y. Reiter. 2002. A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells. Cancer Immunol. Immunother. 51: 565-573.
23. Mosquera, L. A., K. F. Card, S. A. Price-Schiavi, H. J. Belmont, B. Liu, J. Builes, X. Zhu, P. A. Chavaillaz, H. I. Lee, J. A. Jiao, et al. 2005. In vitro and in vivo characterization of a novel antibody-like single-chain TCR human IgG1 fusion protein. J. Immunol. 174: 4381-4388.
24. Subbramanian, R. A., C. Moriya, K. L. Martin, F. W. Peyerl, A. Hasegawa, A. Naoi, H. Chhay, P. Autissier, D. A. Gorgone, M. A. Lifton, et al. 2004. Engineered T-cell receptor tetramers bind MHC-peptide complexes with high affinity. Nat. Biotechnol. 22: 1429-1434.
25. Laugel, B., J. M. Boulter, N. Lissin, A. Vuidepot, Y. Li, E. Gostick, L. E. Crotty, D. C. Douek, J. Hemelaar, D. A. Price, B. K. Jakobsen, and A. K. Sewell. 2005. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J. Biol. Chem. 280: 1882-1892.
26. Li, Y., R. Moysey, P. E. Molloy, A. L. Vuidepot, T. Mahon, E. Baston, S. Dunn, N. Liddy, J. Jacob, B. K. Jakobsen, and J. M. Boulter. 2005. Directed evolution of human T-cell receptors with picomolar affinities by phage display. Nat. Biotechnol. 23: 349-354.
27. + cytotoxic T lymphocytes from patients with HTLV-1-associated disease: evidence for oligoclonal expansion. J. Virol. 70: 843-851.
28. Chen, J. L., P. R. Dunbar, U. Gileadi, E. Jager, S. Gnjatic, Y. Nagata, E. Stockert, D. L. Panicali, Y. T. Chen, A. Knuth, L. J. Old, and V. Cerundolo. 2000. Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 165: 948-955.
29. Boulter, J. M., M. Glick, P. T. Todorov, E. Baston, M. Sami, P. Rizkallah, and B. K. Jakobsen. 2003. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng. 16: 707-711.
30. Lethe, B., S. Lucas, L. Michaux, C. De Smet, D. Godelaine, A. Serrano, E. De Plaen, and T. Boon. 1998. LAGE-1, a new gene with tumor specificity. Int. J. Cancer. 76: 903-908.
31. Purbhoo, M. A., D. J. Irvine, J. B. Huppa, and M. M. Davis. 2004. T cell killing does not require the formation of a stable mature immunological synapse. Nat. Immunol. 5: 524-530.
32. Irvine, D. J., M. A. Purbhoo, M. Krogsgaard, and M. M. Davis. 2002. Direct observation of ligand recognition by T cells. Nature 419: 845-849.
33. Bownds, S., P. Tong-On, S. A. Rosenberg, and M. Parkhurst. 2001. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J. Immunother. 24: 1-9.
34. Chen, J. L., G. Stewart-Jones, G. Bossi, N. M. Lissin, L. Wooldridge, E. M. Choi, G. Held, P. R. Dunbar, R. M. Esnouf, M. Sami, et al. 2005. Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 201: 1243-1255.
35. Bachmair, A., D. Finley, and A. Varshavsky. 1986. In vivo half-life of a protein is a function of its amino-terminal residue. Science 234: 179-186.
36. Johnsson, N., and A. Varshavsky. 1994. Ubiquitin-assisted dissection of protein transport-across membranes. EMBO J. 13: 2686-2698.
37. Valmori, D., U. Gileadi, C. Servis, P. R. Dunbar, J. C. Cerottini, P. Romero, V. Cerundolo, and F. Levy. 1999. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189: 895-906.
38. Chen, Y. T., A. O. Gure, S. Tsang, E. Stockert, E. Jager, A. Knuth, and L. J. Old. 1998. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc. Natl. Acad. Sci. USA 95: 6919-6923.
39. - T cell clones. Cancer Immun. 4: 15.
40. Vaughan, H. A., S. Svobodova, D. Macgregor, S. Sturrock, A. A. Jungbluth, J. Browning, I. D. Davis, P. Parente, Y. T. Chen, E. Stockert, et al. 2004. Immunohistochemical and molecular analysis of human melanomas for expression of the human cancer-testis antigens NY-ESO-1 and LAGE-1. Clin Cancer Res. 10: 8396-8404.
41. Yewdell, J. W., E. Reits, and J. Neefjes. 2003. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat. Rev. Immunol. 3: 952-961.
42. Holler, P. D., P. O. Holman, E. V. Shusta, S. O'Herrin, K. D. Wittrup, and D. M. Kranz. 2000. In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc. Natl. Acad. Sci. USA 97: 5387-5392.
43. Holler, P. D., L. K. Chlewicki, and D. M. Kranz. 2003. TCRs with high affinity for foreign pMHC show self-reactivity. Nat. Immunol. 4: 55-62.
44. Hausmann, S., W. E. Biddison, K. J. Smith, Y. H. Ding, D. N. Garboczi, U. Utz, D. C. Wiley, and K. W. Wucherpfennig. 1999. Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures. J. Immunol. 162: 5389-5397.
45. Hausmann, S., W. E. Biddison, K. J. Smith, Y. H. Ding, D. N. Garboczi, U. Utz, D. C. Wiley, and K. W. Wucherpfennig. J. Immunol. Vol. 176 No. 12